BioTuesdays

Category - Markets

Avedro
Markets

SVB Leerink starts Avedro at OP; PT $20

SVB Leerink initiated coverage of Avedro (NASDAQ:AVDR) with an “outperform” rating and $20 price target. The stock closed at $11.70 on March 8. Analyst Danielle Antalffy writes that the company’s key growth driver is...

March 11, 2019
Anchiano Therapeutics
Markets

Ladenburg starts Anchiano Therapeutics at buy; PT $20

Ladenburg Thalmann initiated coverage of Anchiano Therapeutics (NASDAQ:ANCN) with a “buy” rating and $20 price target. The stock closed at $7.72 on March 8. Anchiano is focused on applying its gene therapy technology as...

March 11, 2019
Gritstone Oncology
Markets

HCW starts Gritstone Oncology at buy; PT $17

H.C. Wainwright launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $17 price target. The stock closed at $11.64 on March 6. Gritstone is focused on developing novel neoantigen-targeting...

March 7, 2019
T2 Biosystems Logo
Markets

Canaccord recommends buying T2 Biosystems on weakness

Canaccord Genuity reiterated its “buy” rating and $10 price target for T2 Biosystems (NASDAQ:TTOO), saying, “We would buy on weakness.” The stock was quoted at $3.71, down 58 cents, or 13%, in afternoon trading on March...

March 5, 2019
Markets

SVB Leerink starts MannKind at OP; PT $3

SVB Leerink initiated coverage of MannKind (NASDAQ:MNKD) with an “outperform” rating and a 12-month price target of $3. The stock closed at $1.77 on March 1. Analyst Dr. Pasha Sarraf writes that his rating is based on...

March 4, 2019
OpGen Logo
Markets

AGP starts OpGen at buy; PT $2.30

AGP/Alliance Global Partners launched coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and price target of $2.30. The stock closed at $1.48 on March 1. “OpGen’s approach to antibiotic resistance identification...

March 4, 2019